OR9G4 Activators
OR9G4 can engage in various mechanisms to initiate its activation. Forskolin, by directly stimulating adenylyl cyclase, leads to an elevation of cyclic AMP (cAMP) within the cell. This rise in cAMP can then activate protein kinase A (PKA), which in turn may phosphorylate and activate OR9G4. Similarly, isoproterenol, by binding to beta-adrenergic receptors, promotes the activation of adenylyl cyclase, thereby increasing intracellular cAMP levels, which could activate OR9G4 if it is coupled to a cAMP-dependent pathway. Prostaglandin E2 (PGE2) interacts with its specific G-protein coupled receptors (GPCRs) that also trigger signaling cascades that result in the production of cAMP, which may lead to the activation of OR9G4. Histamine, another molecule, can bind to its receptors on the cell surface, which may lead to increased cAMP or calcium levels in the cell, and if OR9G4 is responsive to these signals, activation may occur.
3-Isobutyl-1-methylxanthine (IBMX), through its inhibition of phosphodiesterases, prevents the breakdown of cAMP, sustaining its levels in the cell and potentially activating OR9G4. Epinephrine, acting through adrenergic receptors, and dopamine, through dopamine receptors, can also result in elevated cAMP levels, which can activate OR9G4 if it is regulated by cAMP-mediated signaling. Adenosine, by binding to its receptors, can modulate cAMP levels, which may influence OR9G4 activation. Cholera toxin exerts its effect by continuously activating the Gs alpha subunit, leading to prolonged cAMP production, which could result in OR9G4 activation. Beyond the cAMP pathway, nitric oxide donors like SNAP release nitric oxide, which activates guanylyl cyclase to increase cGMP levels. If OR9G4 is regulated by cGMP-dependent processes, this could also lead to its activation. Lastly, vardenafil, by inhibiting cGMP-specific phosphodiesterase type 5 (PDE5), prevents cGMP degradation and may enhance OR9G4 activation if its regulatory mechanisms are cGMP-dependent.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that can stimulate adenylyl cyclase activity via the beta-adrenergic receptor, increasing intracellular cAMP levels, which may lead to activation of OR9G4 if the protein is part of a cAMP-dependent pathway. | ||||||
Adenosine 3′,5′-cyclic monophosphate | 60-92-4 | sc-217584 sc-217584A sc-217584B sc-217584C sc-217584D sc-217584E | 100 mg 250 mg 5 g 10 g 25 g 50 g | $116.00 $179.00 $265.00 $369.00 $629.00 $1150.00 | ||
Cyclic AMP (cAMP) is a second messenger that can activate protein kinase A (PKA). PKA can then phosphorylate various target proteins, potentially including OR9G4, leading to its activation. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) interacts with its G-protein coupled receptors (GPCRs), which can trigger signaling cascades involving cAMP production, possibly resulting in the activation of OR9G4 if it is responsive to cAMP-mediated signaling. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Histamine can bind to histamine receptors, which are GPCRs, potentially causing an increase in intracellular calcium levels or cAMP, both of which might lead to the activation of OR9G4 if it is responsive to these signaling molecules. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
3-Isobutyl-1-methylxanthine (IBMX) is a non-selective inhibitor of phosphodiesterases, enzymes that degrade cAMP. By inhibiting these enzymes, IBMX can raise cAMP levels, potentially leading to the activation of OR9G4 if it operates within a cAMP-dependent signaling pathway. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine, interacting with adrenergic receptors, can increase cAMP production in cells. Elevated cAMP may activate OR9G4 if the protein's activity is modulated by cAMP-dependent signaling mechanisms. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Dopamine can activate dopamine receptors, which are GPCRs that can affect cAMP levels in the cell. This might lead to the activation of OR9G4 if it is part of a dopamine-responsive pathway. | ||||||
Adenosine | 58-61-7 | sc-291838 sc-291838A sc-291838B sc-291838C sc-291838D sc-291838E sc-291838F | 1 g 5 g 100 g 250 g 1 kg 5 kg 10 kg | $34.00 $48.00 $300.00 $572.00 $1040.00 $2601.00 $4682.00 | 1 | |
Adenosine interacts with adenosine receptors, another class of GPCRs, which can modulate cAMP levels. This interaction could lead to the activation of OR9G4 if it is involved in a pathway regulated by adenosine receptor signaling. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
Vardenafil is a selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE5). By preventing cGMP degradation, vardenafil can increase cGMP levels, potentially leading to the activation of OR9G4 if the protein has cGMP-dependent activation mechanisms. | ||||||